United Therapeutics Chairperson and CEO Martine A. Rothblatt sold 9,500 shares of the company’s common stock for approximately $5.72 million on November 3, 2026. The shares were sold at prices ranging from $598.10 to $606.10 each.
The sale followed Rothblatt’s exercise of 9,500 stock options at $117.76 per share, an acquisition valued at approximately $1.12 million. Both transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.
The plan is scheduled to remain in effect until 1,734,410 options have been exercised or December 31, 2026, whichever comes first. The options expire on March 15, 2027.
After the transactions, Rothblatt directly held 40,513 shares. Her reported indirect holdings include shares held in family trusts, some of which she or her spouse manage or have investment power over, as well as 166 shares held by her spouse.
United Therapeutics recently reported record third-quarter revenue of $832.5 million, above the cited Wall Street estimate of $785.44 million. Tyvaso generated $503.8 million in revenue. Earnings per share were $5.71, below the forecast of $6.21. Raymond James maintained an Outperform rating and raised its price target from $717 to $720.
Sources: Investing.com News.